Chemotherapy-related toxicity in infants treated according to the second National Wilms' Tumor Study

Elaine R Morgan, E. Baum, N. Breslow, J. Takashima, G. D'Angio

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Babies under 12 months of age have been included in the National Wilms' Tumor Study (NWTS) series of clinical trials. Undue chemotherapy-related toxicity was encountered early during the course of the second NWTS. The prescribed doses of actinomycin D (AMD), vincristine (VCR), and Adriamycin ([ADR] doxorubicin; Adria Laboratories, Columbus, OH) were therefore halved. The frequency of severe hematologic toxic episodes was reduced (30 of 64 or 47% for babies receiving full doses [FD], and six of 48 or 13% for those given reduced doses [RD]). Similar reductions in pulmonary and hepatic effects were noted, and treatment-related deaths were reduced from 6% to 0 for the FD and RD samples, respectively. These frequencies among RD babies were similar to those encountered in 530 older children administered FD. Reduction of dose did not compromise therapeutic effectiveness.

Original languageEnglish (US)
Pages (from-to)51-55
Number of pages5
JournalJournal of Clinical Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 1988

Fingerprint

Wilms Tumor
Doxorubicin
Drug Therapy
Poisons
Dactinomycin
Vincristine
Clinical Trials
Lung
Liver
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Morgan, Elaine R ; Baum, E. ; Breslow, N. ; Takashima, J. ; D'Angio, G. / Chemotherapy-related toxicity in infants treated according to the second National Wilms' Tumor Study. In: Journal of Clinical Oncology. 1988 ; Vol. 6, No. 1. pp. 51-55.
@article{cd00536846cd46d5983ad31555e06188,
title = "Chemotherapy-related toxicity in infants treated according to the second National Wilms' Tumor Study",
abstract = "Babies under 12 months of age have been included in the National Wilms' Tumor Study (NWTS) series of clinical trials. Undue chemotherapy-related toxicity was encountered early during the course of the second NWTS. The prescribed doses of actinomycin D (AMD), vincristine (VCR), and Adriamycin ([ADR] doxorubicin; Adria Laboratories, Columbus, OH) were therefore halved. The frequency of severe hematologic toxic episodes was reduced (30 of 64 or 47{\%} for babies receiving full doses [FD], and six of 48 or 13{\%} for those given reduced doses [RD]). Similar reductions in pulmonary and hepatic effects were noted, and treatment-related deaths were reduced from 6{\%} to 0 for the FD and RD samples, respectively. These frequencies among RD babies were similar to those encountered in 530 older children administered FD. Reduction of dose did not compromise therapeutic effectiveness.",
author = "Morgan, {Elaine R} and E. Baum and N. Breslow and J. Takashima and G. D'Angio",
year = "1988",
month = "1",
day = "1",
doi = "10.1200/JCO.1988.6.1.51",
language = "English (US)",
volume = "6",
pages = "51--55",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

Chemotherapy-related toxicity in infants treated according to the second National Wilms' Tumor Study. / Morgan, Elaine R; Baum, E.; Breslow, N.; Takashima, J.; D'Angio, G.

In: Journal of Clinical Oncology, Vol. 6, No. 1, 01.01.1988, p. 51-55.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy-related toxicity in infants treated according to the second National Wilms' Tumor Study

AU - Morgan, Elaine R

AU - Baum, E.

AU - Breslow, N.

AU - Takashima, J.

AU - D'Angio, G.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Babies under 12 months of age have been included in the National Wilms' Tumor Study (NWTS) series of clinical trials. Undue chemotherapy-related toxicity was encountered early during the course of the second NWTS. The prescribed doses of actinomycin D (AMD), vincristine (VCR), and Adriamycin ([ADR] doxorubicin; Adria Laboratories, Columbus, OH) were therefore halved. The frequency of severe hematologic toxic episodes was reduced (30 of 64 or 47% for babies receiving full doses [FD], and six of 48 or 13% for those given reduced doses [RD]). Similar reductions in pulmonary and hepatic effects were noted, and treatment-related deaths were reduced from 6% to 0 for the FD and RD samples, respectively. These frequencies among RD babies were similar to those encountered in 530 older children administered FD. Reduction of dose did not compromise therapeutic effectiveness.

AB - Babies under 12 months of age have been included in the National Wilms' Tumor Study (NWTS) series of clinical trials. Undue chemotherapy-related toxicity was encountered early during the course of the second NWTS. The prescribed doses of actinomycin D (AMD), vincristine (VCR), and Adriamycin ([ADR] doxorubicin; Adria Laboratories, Columbus, OH) were therefore halved. The frequency of severe hematologic toxic episodes was reduced (30 of 64 or 47% for babies receiving full doses [FD], and six of 48 or 13% for those given reduced doses [RD]). Similar reductions in pulmonary and hepatic effects were noted, and treatment-related deaths were reduced from 6% to 0 for the FD and RD samples, respectively. These frequencies among RD babies were similar to those encountered in 530 older children administered FD. Reduction of dose did not compromise therapeutic effectiveness.

UR - http://www.scopus.com/inward/record.url?scp=0023853292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023853292&partnerID=8YFLogxK

U2 - 10.1200/JCO.1988.6.1.51

DO - 10.1200/JCO.1988.6.1.51

M3 - Article

VL - 6

SP - 51

EP - 55

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -